EUCTR2009-018025-73-DE进行中（未招募）不适用
Randomised phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- or third-line treatment of patients with metastatic breast cancer - PASO-Trial
GMIHO mbH0 个研究点开始时间: 2010年3月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Histologically or cytologically confirmed adenocarcinoma of the breast
- •2.HER-2/neu negative (primary tumour site HER-2/neu negative by ICH/FISH test)
- •3.Second till third-line of cytostatics based chemotherapy
- •4.Female, age = 18 years.
- •5.ECOG Performance Status of 0 or 1 (Karnofsky-Index = 70%)
- •6.Life expectancy of at least 12 weeks.
- •7.Subjects with at least one uni-dimensional (for RECIST 1.1) measurable lesion.
- •Lesions must be measured by Xray (pulmonary lesions only) or CT-scan or MRI (Patients with only measurable bone lesions can be also included, as long they meet the criteria for RECIST 1.1. Means, lytic bone lesions or mixed lytic-blastic bone lesions with identifiable soft tissue components.)
- •8.No prior therapy for locally recurrent or metastatic disease with TKI’s (RAS/Raf, MEK, AKT), mTOR inhibitors and angiogenesis inhibitors (VEGV/VEGFR, PDGF/PDGFR) but bevacizumab will be allowed.
- •9.Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •Hemoglobin = 9.0 g/dl
- •Absolute neutrophil count (ANC) = 1,500/mm3
- •Platelet count = 100,000/µl
- •Total bilirubin = 1.5 x upper limit of normal
- •ALT and AST = 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer)
- •Alkaline phosphatase = 4 x upper limit of normal
- •PT-INR and PTT = 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.]
- •Serum creatinine = 1.5 x upper limit of normal.
- •10.Signed and dated informed consent before the start of specific protocol procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 148
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 148
排除标准
- •1.History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
- •2.Known history of HIV infection or chronic hepatitis B or C
- •3.Active clinically serious infections (> grade 2 NCI-CTC version 4.0)
- •4.Prior clinical or radiological evidence of CNS metastases including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement by contrast enhanced head CT scan or MRI
- •5.Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •6.History of organ allograft
- •7.Patients with evidence or history of bleeding diathesis
- •8.Patients undergoing renal dialysis
- •9.Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumours [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •10.Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
- •11.Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results
- •12.Any condition that is unstable or could jeopardise the safety of the patient and their compliance in the study
- •13.Patients unable to swallow oral medications.
- •14. Patients with intolerance to Paclitaxel
研究者
相似试验
进行中（未招募）
1 期
A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma - Paclitaxel +/- GSK1120212 in MelanomaEUCTR2011-002545-35-GBniversity of Oxford111
进行中（未招募）
1 期
A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma - Paclitaxel +/- GSK1120212 or pazopanib in MelanomaEUCTR2011-002545-35-DEniversity of Oxford138
进行中（未招募）
1 期
A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancerAdvanced, recurrent epithelial ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033160Term: Ovarian epithelial cancer recurrentEUCTR2006-007013-20-DKOnkologisk afdeling R and the Unit for Experimental Chemotherapy70
招募中
不适用
Randomized Evaluation of Paclitaxel-eluting versus Everolimus-eluting stent Trialcoronary artery diseaseJPRN-UMIN000004177Division of Cardiovascular Medicine, Wakayama Medical University800
已完成
2 期
A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT1210029107non-small cell lung cancerNL-OMON36516Stichting NVALT studies222